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Abstract 1 
Purpose: To estimate the yearly rate of change of best corrected visual acuity (BCVA) and 2 
the risk of loss ≥1 lines over one year, and to identify risk factors for BCVA loss in patients 3 
with Stargardt disease (STGD1). 4 
Design: Multi-center prospective cohort study. 5 
Participants:  259 patients (489 study eyes) with molecularly confirmed STGD1 enrolled at 6 
nine centers in the USA and Europe.  7 
Methods: Participants were followed every six months, and data at baseline, six and 12-8 
month visits were analyzed. BCVA was measured using the ETDRS protocol. Standardized 9 
reporting forms were used to collect participants’ characteristics and clinical observations. 10 
Linear mixed effects models were used to estimate the rate of BCVA loss. Linear models with 11 
generalized estimating equations were used to identify risk factors for BCVA loss ≥1 lines 12 
over one year.  13 
Main Outcome Measures: BCVA change over one year. 14 
Results: Cross-sectional analysis at baseline showed that earlier symptom onset and longer 15 
duration since onset was associated with worse BCVA. Longitudinal analysis showed no 16 
overall significant change of BCVA within 12 months, but the rate of BCVA change was 17 
significantly different by baseline BCVA (p<.001). BCVA of eyes with baseline BCVA better 18 
than or equal to 20/25 declined at a rate of 2.8 ETDRS letters per year (p=.10); eyes with 19 
baseline BCVA between 20/25 and 20/70 declined at a rate of 2.3 ETDRS letters per year 20 
(p=.002); eyes with baseline BCVA between 20/70 and 20/200 declined at a rate of 0.8 21 
ETDRS letters per year (p=.08); and eyes with baseline BCVA worse than 20/200 showed a 22 
significant improvement of 2.3 ETDRS letters per year (p<.001). Overall, 12.9% eyes lost ≥1 23 
lines, and the risk of such BCVA loss was different by baseline BCVA level (p=.016). 24 
Smoking and vitamin A use was not significantly associated with baseline BCVA, nor with 25 
rate of BCVA loss over one year. 26 
Conclusions: BCVA change in STGD1 over a 12 month period was small, but the change 27 
varied depending on baseline BCVA. Given the slow change during one year, BCVA is 28 
unlikely to be a sensitive outcome measure for STGD1 treatment trials with one year 29 
duration.  30 
31 
 4 
Introduction 32 
Stargardt disease (STGD1; OMIM: 248200) is the most common juvenile macular dystrophy 33 
with a prevalence of 10-12.5 per 100,000 persons1, and is inherited as an autosomal-recessive 34 
trait associated with mutations in the ABCA4 gene2. It is characterized by the appearance of 35 
yellowish-white lesions called fundus flecks at the level of the retinal pigment epithelium 36 
(RPE) and by the development of macular atrophic lesions. Patients with STGD1 are known 37 
to experience impairment of visual acuity progressively and at various ages. Currently there is 38 
no approved treatment for the disease. Understanding the natural history of STGD1 and 39 
determining the rate of disease progression using multiple functional or structural methods is 40 
of great interest for determining appropriate outcome measures in clinical trials of potential 41 
treatments3-8.  42 
 43 
Prior studies reporting the rate of change of visual acuity (VA) in STGD19-15 were all based 44 
on retrospective review of medical records. In this study, we used data from the prospective 45 
international multi-center study of the natural history of the Progression of Atrophy 46 
Secondary to Stargardt Disease (ProgStar), to assess the rate of VA change and identify 47 
participants’ demographic, clinical and behavioral characteristics associated with VA loss 48 
over one year.  49 
 50 
Participants and Methods 51 
Data for this analysis are from the prospective ProgStar study which was approved by the 52 
Western Institutional Review Board, the local institutional review boards, and the Human 53 
Research Protection Office of the United States Army Medical Research and Materiel 54 
Command. The study was registered at www.clinicaltrials.gov (identifier, NCT01977846). 55 
 56 
 57 
 5 
Details of the prospective ProgStar study have been described in detail elsewhere7. In brief, 58 
from September of 2014 to March 2015, eligible STGD1 patients were enrolled into the 59 
ProgStar study at nine participating sites from the USA, United Kingdom, France and 60 
Germany. Eligibility of participants included: age≥6 years; willingness to undergo ocular 61 
examinations every 6 months for up to 24 months; having two pathogenic mutations in the 62 
ABCA4 gene, or, having one pathogenic mutation in the ABCA4 gene together with a typical 63 
Stargardt phenotype such as flecks at the level of the RPE (further inclusion and exclusion 64 
criteria are described in ProgStar Report #1)7.  The particularly relevant inclusion criteria for 65 
analysis herein are that study eyes had to have a best corrected visual acuity (BCVA) ≥20 66 
ETDRS letters (i.e. 20/400 Snellen equivalent or better); have at least one well-demarcated 67 
area of atrophy on fundus autofluorescence imaging with a diameter≥ 300 microns and the 68 
sum of all lesions ≤12 mm2; and have clear ocular media and adequate pupillary dilation per 69 
site investigators’ assessment. All participants gave written informed consent prior to 70 
enrollment in the study. 71 
 72 
Participants were followed every six months. At each visit, participants underwent detailed 73 
ophthalmic examinations; refraction and best corrected visual acuity (BCVA) was obtained 74 
following the ETDRS (Early Treatment of Diabetic Retinopathy Study) protocol16 at all sites. 75 
For data collection, a standardized demographic form and clinical report form (CRF) was 76 
used at all sites to record age, sex, race, age of symptom onset and clinical information on 77 
BCVA, results from the biomicroscopy of the anterior segments and dilated fundus 78 
examination, and behavioral characteristics (use of vitamin supplementation, smoking 79 
history) at each study visit. All data were double entered by study coordinators into the 80 
REDCap (Research Electronic Data Capture) system (http://www.project-81 
redcap.org/cite.php), and transferred to Data Coordinating Center for data quality control and 82 
management. 83 
 6 
 84 
Statistical analysis 85 
Data from the baseline, 6 month and 12 month visits were used in this analysis. Participant 86 
demographic and clinical characteristics at baseline visit were first summarized. Baseline 87 
BCVA was also categorized in referencing the World Health Organization's International 88 
Classification of Diseases, 10th revision17 and as (1) VA ≥20/25 (i.e logarithm of the 89 
minimum angle of resolution [logMAR] ≤0.1 or ETDRS letters ≥80) (i.e., no visual 90 
impairment [VI]); (2) worse than 20/25 to 20/70 (logMAR 0.1–0.54, i.e. ETDRS letters 58-91 
80) (i.e., mild VI); (3) worse than 20/70 to 20/200 (logMAR 0.54–1.0, i.e. ETDRS letters 92 
35-58) (i.e., moderate VI); (4) worse than 20/200 to 20/400 (logMAR 1.0–1.3, i.e. ETDRS 93 
letters 20-35) (i.e., severe VI); and (5) worse than 20/400 (logMAR >1.3, i.e. ETDRS letters 94 
<20) (i.e., blindness).  95 
 96 
For all analyses, ETDRS letter scores were converted to the logMAR scale. Baseline data of 97 
participants and study eyes were used to explore the cross-sectional association of BCVA 98 
with participant demographic and behavioral characteristics including age (categorized as 99 
<=18, >18-50, 50+ years), sex, race (white vs. non-white), smoking status and vitamin A use, 100 
and with clinical characteristics including age at symptom onset (categorized into ≤14, 15-20, 101 
21-30, 30+ years upon considering data distribution and prior publications) and duration since 102 
symptom onset at baseline (categorized as 0-2, >2-6, >6-11.5 and >11.5-53 years upon 103 
considering data distribution and prior publications). Age, age of symptom onset, and 104 
duration since onset were also modeled as continuous variables in separate models. Eye-level 105 
clinical characteristics included observations from biomicroscopy of the anterior segments 106 
and dilated fundus examination. Univariate linear models with generalized estimating 107 
equations (GEE) were used to estimate the unadjusted cross-sectional associations while 108 
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accounting for between-eye correlation, followed by multivariate linear models with GEE to 109 
estimate the associations adjusting for variables associated with BCVA in univariate analyses 110 
with p<0.1.   111 
 112 
To estimate the longitudinal change of BCVA, a linear mixed effects model (LMM) was used 113 
to estimate the yearly change rate: the mean of participants’ BCVA was modeled as a linear 114 
function of time since baseline visit, with the intercept and slope parameters assumed to be 115 
normally distributed random effects. Additionally, BCVA change from baseline to year 1 was 116 
further dichotomized as whether or not there was a loss of one or more lines (i.e. loss of 5 or 117 
more ETDRS letters), and the proportion of such loss was estimated. Univariate log-binomial 118 
models with GEE were used to estimate the risk ratios of baseline variables (for the 119 
behavioral variable of vitamin A use, the report at year 1 visit was considered) in association 120 
with the risk of one or more lines of BCVA loss during the year. Multivariate log-binomial 121 
models with GEE were used to estimate the adjusted risk ratios for variables associated with 122 
risk of BCVA loss of one or more lines in univariate analysis with p≤0.10 and for variables 123 
associated with baseline BCVA with p≤0.10.  124 
 125 
All analyses were conducted in SAS 9.3, and two-sided p-values from Wald-tests were 126 
reported. For analyses using GEE models, model fit was assessed using aggregated 127 
residuals18, and for the longitudinal analysis using LMMs, model fit was inspected visually 128 
and based on plots of scaled residuals.19  129 
 130 
Results 131 
There were 259 participants with 489 study eyes enrolled in the prospective ProgStar study. 132 
Follow-up rate was 92% at Month 6 and 93% at Month 12 (Figure 1).  Table 1 summarizes 133 
characteristics of participants and their study eyes. The median age at baseline was 31 134 
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(interquartile range [IQR] 21-44) years, and 54% (N=141) were female. Most participants 135 
were white (N=222, 86%), 7.7% were black (N=20), and 4% were Asian (N=10). The median 136 
age of self-reported age of symptom onset was 19 (IQR 12-29) years, and the median duration 137 
since symptom onset at the baseline visit was 9 (IQR 5-15) years. Vitamin A use was reported 138 
by 37 (14%) participants (a summary of dosage and frequency is presented in Supplemental 139 
Table 1). Current smoking was reported in 29 (11%) participants, and 35 (14%) were former 140 
smokers.  141 
 142 
At baseline, the median BCVA of the study eyes was 41 (IQR 35-52, range 20-88) ETDRS 143 
letters (i.e. median LogMAR=0.88), and 21% eyes had no or mild visual impairment (VI), 144 
55% were moderately impaired, and 25% were severely impaired. Lens change or 145 
abnormalities of the anterior segment were rare. Clinical exam data showed that 9.5% eyes 146 
had nerve pallor, 93% eyes had RPE atrophy, and 67% eyes had RPE pigmentary abnormality 147 
(i.e. hypo- and/or hyper-pigmentations at the level of the RPE). Most eyes (92%) had flecks 148 
present within the arcades, and 46% eyes had flecks outside the arcades (Table 1).  149 
  150 
Cross-sectional associations of participant characteristics with baseline BCVA 151 
Table 2 presents the baseline BCVA in subgroups by participant characteristics, and the 152 
difference of BCVA between subgroups. Compared to participants with age ≤18 years, the 153 
BCVA of those aged 18-50 years and those aged >50 years was better by 4.5 and 10.5 154 
ETDRS letters (i.e ~0.09 and 0.21 LogMAR difference) respectively. Such differences 155 
however were not significant in adjusted analysis. When age was modeled as a continuous 156 
variable, older age was associated with better BCVA in univariate analysis (p=.007). But in 157 
multivariate analysis controlling for age of symptom onset, older age was associated with 158 
worse BCVA (adjusted p=0.02). There was no significant difference in BCVA by sex or by 159 
race.  Older age of symptom onset was significantly associated with better BCVA (p<.001): 160 
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for example, compared to participants with onset age ≤14 years, the BCVA of those with 161 
onset age>30 years was 11.5 ETDRS letters better (i.e. adjusted logMAR difference -0.23). 162 
Such an association was also significant when age of onset was modeled as a continuous 163 
variable (adjusted p<.001). Longer duration of symptoms was significantly associated with 164 
worse BCVA (p<.001): e.g. compared to participants with symptoms ≤2 years, the BCVA of 165 
those with symptoms for >11.5 years was 13 ETDRS letters worse (i.e. adjusted LogMAR 166 
difference 0.26). The association was also significant when duration was modeled as a 167 
continuous variable (adjusted p<.001). For behavioral variables, vitamin A use was not 168 
associated with BCVA (p=0.34). The BCVA of current smokers was 5 ETDRS letters (i.e 169 
logMAR difference 0.1) worse than never smokers, but this difference was not statistically 170 
significant (p=0.26) 171 
 172 
For eye-level clinical characteristics, having nerve pallor and flecks within the arcades was 173 
not associated with worse BCVA. BCVA of eyes with RPE pigmentary abnormalities was 5 174 
ETDRS letters (i.e. LogMAR difference 0.1, adjusted p=.003) worse than eyes without this 175 
abnormality; BCVA of eyes with flecks outside the arcades was 6 ETDRS letters (i.e. 176 
LogMAR difference 0.12, adjusted p<.001) worse than eyes without flecks outside the 177 
arcades. Associations of BCVA with other fundus examination variables were not assessed 178 
due to the small sample sizes in certain subgroups.  179 
 180 
Longitudinal analysis of the yearly change of BCVA   181 
Overall there was no statistically or clinically significant change of mean BCVA over 12 182 
months (Figure 2): the rate of change was -0.36 ETDRS letters (0.007 LogMAR)/year (95% 183 
CI: (-1.18, 0.46) ETDRS letters; p=0.38). However, the change was statistically significantly 184 
different by baseline BCVA level (p<.001) (Table 3 and Figure 3): eyes with no VI at 185 
baseline (N=17) had a non-significant BCVA change of -2.8 ETDRS letters (0.056 186 
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LogMAR)/year (95% CI: -6.01, 0.49 ETDRS letters); eyes with mild VI (N=83) showed a 187 
significant BCVA change of -2.3 ETDRS letters (0.047 LogMAR)/year (95% CI: -3.86, -0.83 188 
ETDRS letters); eyes with moderate VI (N=267) showed a non-significant BCVA change of -189 
0.8 ETDRS letters (0.015 LogMAR)/year (95% CI: -1.59, 0.09 ETDRS letters); and eyes with 190 
severe VI (N=122) had a statistically significant gain of 2.3 ETDRS letters (-0.045 191 
LogMAR)/year (95% CI: 1.00, 3.52 ETDRS letters). These change rates (Table 3) suggested 192 
a dose-response relationship between baseline BCVA level and the rate of BCVA change. We 193 
therefore modeled baseline BCVA as continuous in the linear mixed effects model which 194 
confirmed that the better the baseline BCVA, the larger the BCVA decline over one year 195 
(p<.001). 196 
 197 
Longitudinal analysis of the factors associated with risk of loss of one or more lines from 198 
baseline to 12 month visit 199 
Among the 456 study eyes observed at baseline and month 12, the proportion losing one or 200 
more lines was 12.9% (59/456). The risk of such loss was significantly different by baseline 201 
BCVA level (adjusted p=0.02): it was 11.8%, 25%, 12.7% and 5.5%, respectively, in eyes 202 
without VI, with mild, moderate, or severe VI at baseline (Table 4). The risk of BCVA loss 203 
was also significantly different by age of symptom onset (adjusted p=0.03): in particular, 204 
compared to participants with symptom onset age ≤14 years, the risk of BCVA loss was 66% 205 
lower in participants with symptom onset age between 15 and 20 years (adjusted risk ratio 206 
[RR]=0.34, 95%CI: 0.14-0.82). BCVA loss of one or more lines at one year was not 207 
associated with duration of symptoms at baseline, vitamin A use (at year 1), smoking status, 208 
and having nerve pallor, RPE pigmentary abnormalities, or flecks within the arcades. Having 209 
flecks outside arcades was associated with lower risk of BCVA loss in univariate analysis, but 210 
the association was not significant in adjusted analysis.  211 
 212 
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Discussion 213 
We reported the demographic and clinical characteristics and change of BCVA during one 214 
year for STGD1 patients enrolled in the multi-center ProgStar prospective study.  Our 215 
longitudinal analysis found that the rate of BCVA change was significantly different by 216 
baseline BCVA level, but overall there was no significant change over one year of follow-up 217 
(estimated rate=0.007 LogMAR/year). This finding differs from our ProgStar retrospective 218 
cohort20 where BCVA declined at a small but statistically significant rate of 0.03 219 
LogMAR/year. The difference between these two findings may be due in part to the 220 
differences in the length of follow-up between our two cohorts:  the current analysis on the 221 
prospective cohort focused on data during one year of follow-up, whereas the retrospective 222 
study had variable but longer follow-up, with a median of 3.6 years. The difference in the two 223 
findings may also be due to the fact that the retrospective cohort had better baseline VA than 224 
the prospective cohort, especially considering that both studies found that the rate of VA 225 
change was significantly different by baseline VA, with better baseline VA associated with a 226 
greater yearly rate of decline. These findings suggest that VA loss in STGD1 is not a linear 227 
process, where loss is greatest at an early stage when a degree of foveal vision is still present 228 
despite accompanying parafoveal degeneration21-23, then BCVA loss slows after foveal vision 229 
is lost and fixation becomes eccentric.  230 
 231 
For eyes without any visual impairment at baseline, there was a loss of VA over one year but 232 
it was not statistically significant. This may be due to the small sample size in the group. The 233 
estimated rates of change in eyes without impairment (0.056 LogMAR/year) and eyes with 234 
mild impairment (0.047 LogMAR/year) were smaller than the estimates in the ProgStar 235 
retrospective cohort (0.096 and 0.094 LogMAR/year, respectively)20. This difference again is 236 
most likely due to the difference in length of follow-up and due to the non-linear process of 237 
BCVA loss in STGD1. The rates of change in eyes with moderate or severe impairment at 238 
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baseline were similar to those estimated in the retrospective study (~0.02 loss and 0.05 gain 239 
LogMAR/year, respectively), suggesting that VA change may be relatively constant at these 240 
stages.  241 
 242 
In particular, similar to our findings in the ProgStar retrospective study and in our analysis 243 
with ProgStar participants with recent onset of symptoms11, 20, we found that eyes with severe 244 
impairment (VA worse than 20/200) at baseline showed a small (~0.5 lines/year) but 245 
statistically significant improvement in VA over time. The improvement may be due to 246 
regression to the mean, where patients with poor vision tested poorly at baseline, and tested 247 
slightly better at subsequent visits reflecting normal variation. Additionally, VA is known to 248 
vary to a greater extent in patients with more severe visual impairment. However, it is also 249 
plausible for VA to improve as a result of change of the location of the preferred retinal locus 250 
(PRL), as has been observed in participants with geographic atrophy and inherited macular 251 
dystrophies 24-27. Also, fixation stability may improve over time28. In the case of STGD1, it is 252 
possible for the PRL to move from a superior retinal locus to the parapapillary region as the 253 
central scotoma expands with disease progression.29 This hypothesis will be tested in 254 
conjunction with the microperimetry data from the ProgStar prospective study.  255 
 256 
In clinical trials, loss of 15 ETDRS letters (equivalent to three Snellen lines) or more are 257 
considered clinically significant30. However, such loss was rare in our cohort during the 12 258 
months: 12 eyes lost three or more lines from baseline to year 1, i.e. a risk of 2.6%.  259 
Clinically, loss of one or more lines may be concerning for patients and their physicians, and 260 
such loss was not rare in our cohort, occurring in 59 (12.9%) eyes. Consistent with the 261 
findings regarding the yearly rates of BCVA change, baseline BCVA level was the strongest 262 
predictor for BCVA loss of one or more lines, with eyes with severe impairment at baseline 263 
having the lowest risk of such loss. For the variable of age of symptom onset, results from the 264 
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multivariable model were similar to those from our retrospective ProgStar study: older age of 265 
symptom onset was associated with lower risk of BCVA loss of one or more lines during the 266 
year. However, in this prospective cohort, the risk of BCVA loss of one or more lines in the 267 
oldest onset age group of (>30 years) was not significantly lower than the youngest onset age 268 
group (≤14 years). This discrepancy could be due to the difference in outcomes in the two 269 
studies: the current analysis considered the dichotomized outcome of BCVA loss of one more 270 
lines during one year (which was of clinical relevance), whereas the retrospective study was 271 
assessing the yearly change rate which used the actual BCVA values (rather than 272 
dichotomized) and which was based on data of variable follow-up lengths among participants. 273 
 274 
Similar to the retrospective study, duration of symptoms, presence of RPE pigmentary 275 
changes, flecks within the arcades and flecks outside the arcades were not associated with the 276 
one-year risk of BCVA loss of one or more lines. We are not aware of prior studies that 277 
assessed the effects of smoking and vitamin A use in STGD1 patients. Our longitudinal 278 
analysis did not find a higher risk of loss of BCVA during the year associated with smoking 279 
and vitamin A use. Since few people used vitamin A (14%) or smoked (11%) in this cohort, it 280 
is possible that the study was underpowered to detect small effects. 281 
 282 
Examination of the brand names of the supplement showed that the supplementation was 283 
often through multivitamin use. The cross-section analysis at baseline showed that baseline 284 
BCVA was not significantly different by smoking or vitamin A use. Other results from the 285 
baseline cross-sectional analysis are similar to prior published studies and to our earlier 286 
findings in the retrospective ProgStar cohort11, 13, 14, 31:  287 
a younger age of symptom onset and a longer duration since symptom onset was associated 288 
with worse VA; and older age was associated with worse VA, which is compatible with the 289 
finding that the longer the duration since symptom onset the poorer is VA.  290 
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  291 
The ProgStar prospective study is a large-scale and the first study of STGD1 with prospective 292 
data collection under a pre-designed standardized study protocol involving multiple sites from 293 
both the US and Europe, greatly increasing generalizability. One limitation of the study herein 294 
is that we inferred that the VA loss trajectory was non-linear in STGD1. However, this 295 
inference was not based on directly observing the VA trajectory over many years from the 296 
same individuals; rather, it was based on data from multiple participants with different current 297 
VA levels and who showed different rates of VA change during one year. Nonetheless, 298 
considering the small rate of change per year, it is reasonable to use linear models to describe 299 
the BCVA change during one year.  300 
 301 
STGD1 patients may present with distinct phenotypes, such as macular atrophy surrounded 302 
by flecks, patchy/mottled foveal changes, bull’s eye maculopathy, foveal sparing, and others8, 303 
32. These phenotypes may be associated with different genetic variants and may have different 304 
VA progression patterns33-35, for example, the foveal sparing phenotype is known to be on the 305 
milder end of the spectrum of the disease, and VA of patients with such phenotype may be 306 
maintained longer34, 36, 37. However, since our clinical data did not record specific phenotype 307 
information, we were unable to assess VA change associated with each phenotype in our 308 
cohort. Nevertheless, utilizing information from fundus autofluoresence image grading, we 309 
will evalute VA in patients with no foveal involvement at baseline in a subsequent ProgStar 310 
report. Another limitation of this report is that at baseline, the study only tested participants 311 
BCVA once using ETDRS protocol, and thus did not control for any potential learning effect 312 
assoicated with the ETDRS chart. However, at least 56% of participants had received ETDRS 313 
VA testing during their routine clinical visits before this study enrollment, and thus learning 314 
effect should be minimal in these participants.  315 
 316 
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BCVA is an important visual function outcome directly related to participants daily activities, 317 
38  and is the most common outcome measure for efficacy studies of retinal diseases 30. 318 
However, our data suggest that the change of BCVA in STGD1 was small and not statistically 319 
significant during one year. . Since it will be difficult for trials aiming to prevent or slow VA 320 
loss to show a difference over a one year period, VA is not sensitive enough to serve as a 321 
primary outcome. Nevertheless, we found that the change of BCVA depended on the starting 322 
level of BCVA, and faster progression was observed in patients with baseline BCVA better 323 
than 20/70. This information may inform planning of future trials that target on patients who 324 
are most likely to show VA loss in 12 months. 325 
 326 
In summary, we found that there was no significant change of BCVA during one year, but 327 
baseline BCVA level was associated with different rates of subsequent BCVA change. We 328 
found that patients with poor vision at baseline showed a small, but statistically significant 329 
gain in visual acuity. Smoking and vitamin A use was not associated with worse BCVA at 330 
baseline, nor associated with higher risk of BCVA loss during the one year follow-up. BCVA 331 
appears to be relatively insensitive to detect changes in a reasonable time period. Therefore, it 332 
is important to explore other potentially more sensitive outcome measures derived from 333 
functional or morphological analysis, such as microperimetry, optical coherence tomography, 334 
adaptive optics, or fundus autofluorescence imaging. 335 
 336 
List of Figure Legends: 337 
Figure 1. Flowchart of enrollment and follow-up of the prospective ProgStar study. 338 
 339 
Figure 2. Spaghetti plot showing visual acuity of the participants during their one year follow-340 
up. Each gray line is data for one eye. The blue line represents the estimated average VA 341 
change: -0.36, 95% CI: (-1.18, 0.46) letters (i.e. 0.007 LogMAR) per year.  342 
 343 
Figure 3. Spaghetti plots showing visual acuity change during one year follow-up by baseline 344 
VA level. Each gray line is data for one eye. The blue line represents the estimated average 345 
VA change. (VI: visual impairement.) 346 
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3A. Visual acuity change in eyes with no visual impairment (i.e. Snellen VA 20/25 347 
or better) at baseline. Rate of change: -2.77 (95%CI -6.02, 0.49) letters/year (i.e. 348 
0.056 LogMAR/year). 349 
 350 
3B. Visual acuity change in eyes with mild visual impairment (Snellen VA between 351 
20/25 and 20/70) at baseline. Rate of change -2.35 (95%CI -3.96, -0.83) letters/year 352 
(i.e. 0.047 LogMAR/year). 353 
 354 
3C. Visual acuity change in eyes with moderate visual impairment (Snellen VA 355 
between 20/70 and 20/200) at baseline. Rate of change -0.75, (95%CI -1.59, 0.09) 356 
letters/year (i.e. 0.015 LogMAR/year).  357 
 358 
3D. Visual acuity change in eyes with severe visual impairment (Snellen VA worse 359 
than 20/200) at baseline. Rate of change 2.26 (95%CI 1.00, 3.52) (i.e. -0.045 360 
LogMAR/year). 361 
 362 
363 
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